Ryvu Therapeutics SA
WSE:RVU
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| PL |
R
|
Ryvu Therapeutics SA
WSE:RVU
|
591.9m PLN |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
213.5B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
154.8B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
81.6T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
36.3B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
273.1B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
37.9B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
34.4B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.5B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
22.9B USD |
Loading...
|
Market Distribution
| Min | -9 940 700% |
| 30th Percentile | -3.7% |
| Median | 2.9% |
| 70th Percentile | 9.1% |
| Max | 196 605.3% |
Other Profitability Ratios
Ryvu Therapeutics SA
Glance View
Ryvu Therapeutics SA engages in the provision of products and solutions for the pharmaceutical and biotechnology industry. The company is headquartered in Krakow, Woj. Malopolskie and currently employs 186 full-time employees. The company went IPO on 2011-07-14. The firm is active in the pharmaceutical and biotechnology fields. The company operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. The company operates through unit Ardigen SA and SORS Holdings Ltd.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Ryvu Therapeutics SA is -170%, which is below its 3-year median of -159.6%.
Over the last 3 years, Ryvu Therapeutics SA’s Net Margin has increased from -468.1% to -170%. During this period, it reached a low of -468.1% on Aug 30, 2022 and a high of -106.3% on Jun 30, 2023.
